Comparing two drugs for Dientamoeba fragilis stomach issues
Part of Digestive system, Infections clinical trials.
This trial tests if paromomycin or metronidazole works better for adults with ongoing stomach problems caused by a parasite called Dientamoeba fragilis. These symptoms (pain, bloating, diarrhea) must have lasted more than a month, and no other cause has been found.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have had stomach or gut symptoms (like pain, bloating, or diarrhea) for more than a month
- A stool test confirmed you have Dientamoeba fragilis and no other infection (except Blastocystis hominis is okay)
- Your symptoms are not explained by another medical condition
- You are not pregnant
- You have not taken metronidazole or paromomycin in the last 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, emodepside, against the standard treatment albendazole for whipworm infection. It aims to see which is safer and works better in adolescents and adults.
This trial tests two different antibiotic combinations (both including bismuth) to see which works better at getting rid of an H. pylori infection in the stomach. The goal is to find a more effective way to clear the infection and reduce stomach problems.
This trial compares three treatments for Clostridioides difficile infection (a severe diarrhea caused by bacteria) to see which works best and prevents it from coming back. It tests a fecal microbiota transplant (FMT, transferring healthy donor stool), fidaxomicin, and vancomycin, all given by mouth or tube.
This study compares two medicines, fidaxomicin and vancomycin, to see which one is better at preventing C. diff infection in people with inflammatory bowel disease who are having a colonoscopy.
This trial tests two medications, acotiamide and itopride, to see which one better relieves symptoms like fullness and bloating after eating. It is for people diagnosed with postprandial distress syndrome (a type of functional dyspepsia).
This Phase 2 study tests whether an investigational treatment can help clear or reduce antibiotic-resistant bacteria living in the gut. It may help prevent these germs from causing future infections by targeting specific resistant bacteria found on stool or rectal swabs.
Hear when a new Dientamoeba Fragilis Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.